Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA
This article was originally published in The Tan Sheet
Executive Summary
LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations
You may also be interested in...
FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban
FDA Commissioner Mark McClellan, MD/PhD, said the "framework" for the outright ban of ephedra will be based on substantive scientific evidence as the agency prepares to publish the reg
LipoKinetix Cases Prompt Support For Mandatory Supplement AE Reporting
Seven hepatotoxicity adverse event reports linked to Syntrax' LipoKinetix weight-loss supplement further support the need for mandatory AE reporting for supplement manufacturers, University of Pennsylvania researchers say
PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.